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Abstract: Multiple system atrophy (MSA) is characterized
clinically by Parkinsonism, cerebellar dysfunction, and auto-
nomic impairment. Multiple mutations in the LRRK2 gene are
associated with parkinsonian disorders, and the most common
one, the G2019S mutation, has been found in 1% of sporadic
cases of Parkinsonism. In a well-characterized cohort of 136
subjects with probable MSA and 110 neurologically evaluated
control subjects, none carried the G2019S mutation. We con-
clude that the G2019S mutation in the LRRK2 gene is unlikely
to be associated with MSA. © 2007 Movement Disorder So-
ciety
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Multiple system atrophy (MSA) is a progressive, de-
generative, neurological disease, which is characterized
by Parkinsonism, cerebellar dysfunction, and autonomic
failure.1,2 The pathological hallmark of the disorder is the
presence of glial cytoplasmic inclusions (GCI) in oligo-
dendrocytes, and a major component of GCI is
-synuclein.3 A number of disorders characterized by
inclusions containing -synuclein have been grouped
together as synucleinopathies, and these diseases include
MSA, Parkinson’s disease (PD), and Lewy body
dementia.4
In 2004, two groups independently reported mutations
in the gene leucine-rich repeat kinase 2 (LRRK2) in
families with autosomal dominant PD mapping to the
*Correspondence to: Laurie Ozelius, Albert Einstein College of
Medicine, Molecular Genetics, Ull 1211, 1300 Morris Park Ave.,
Bronx, NY 10461. E-mail: Ozelius@aecom.yu.edu
Received 16 October 2006; Accepted 17 October 2006
Members of the North American Multiple System Atrophy Study
Group are listed in the Appendix
Published online 17 January 2007 in Wiley InterScience (www.
interscience.wiley.com). DOI: 10.1002/mds.21343
Movement Disorders
Vol. 22, No. 4, 2007, pp. 546–549
© 2007 Movement Disorder Society
546
PARK8 locus.5,6 As a number of the families involved
are of Basque-descent, Paisan-Ruiz et al.5 named the
protein involved dardarin, derived from the Basque word
dardara meaning tremor. Zimprich et al.6 reported that
the common pathological feature in cases with mutations
in this gene was neuronal loss and gliosis in the substan-
tia nigra. Two cases were noted to have Lewy bodies
(one relatively limited to the brainstem and one with
widespread Lewy bodies). However, pleiomorphic pa-
thology was also reported, including one case with pro-
gressive supranuclear palsy-like pathology and one kin-
dred with clinical features of motor neuron disease, a
mild decrease in anterior horn cells, gliosis, and axonal
spheroids. Within months of these reports, a number of
groups identified a specific mutation, G2019S
(6055G3A nucleotide change), not found in the initial
studies, and it is the most common mutation found to
date in familial7,8 and sporadic PD9 in European and
North American populations. The prevalence of this mu-
tation in PD patients varies with ethnicity. It has been
reported to be low in Asians,10 but high in North African
Arabs11 and Ashkenazi Jews.12 The penetrance of this
mutation appears to increase with age, and it may not be
fully penetrant.13
Because of the relatively high frequency of the LRRK2
G2019S mutation in sporadic PD and the observation
that mutations in this gene can be associated with atyp-
ical parkinsonian disorders, we determined the frequency
of this mutation in a carefully characterized cohort of
MSA patients and case–control subjects.
SUBJECTS AND METHODS
The study, which is part of an ongoing study of envi-
ronmental and genetic risk factors for MSA, was con-
ducted in accordance with the Declaration of Helsinki.
Subjects were enrolled at 11 sites in the United States:
University of California, San Diego; Parkinson’s Insti-
tute; Mayo Clinic; University of Michigan; Case West-
ern Reserve University; Baylor College of Medicine;
University of Virginia; University of Maryland; Univer-
sity of Pennsylvania; University of Rochester; Boston
University. The protocol was approved by the Institu-
tional Review Board at each site and the Albert Einstein
College of Medicine, and the subjects were enrolled after
the study had been carefully explained and the subjects
had signed an informed consent. Two hundred and forty-
six subjects were evaluated for the mutation: 136 MSA
patients and 110 control subjects. All individuals were
evaluated with a medical history, neurological examina-
tion, and the Unified MSA Rating Scale.14 The neurolo-
gists evaluating the subjects had all participated in a
validation process to ensure consistent evaluation of the
subjects and application of the Unified MSA Rating
Scale. All MSA subjects were diagnosed with probable
MSA according to the Consensus Criteria.15 The MSA
subjects were classified as having the parkinsonian vari-
ant of MSA (MSA-P), if the symptoms of Parkinsonism
developed a year or more before cerebellar dysfunction,
or the cerebellar variant of MSA (MSA-C), if the symp-
toms of cerebellar dysfunction developed a year or more
before Parkinsonism. If the data did not clearly indicate
whether Parkinsonism or cerebellar dysfunction occurred
first, then the MSA subjects were defined as mixed
(MSA-mixed). The control subjects exhibited no symp-
toms or signs indicative of MSA. Designation of ethnic-
ity and race was based on self-reporting. Each subject
was assigned an anonymous ID code. Blood was drawn
from all participants.
DNA was extracted from white blood cells using the
Puregene procedure (Gentra Systems, Minneapolis,
MN). The G2019S mutation in LRRK2 was genotyped
by Pyrosequencing (Biotage, Uppsala, Sweden) using
the methods and primers described.12
RESULTS
The mean age at disease onset in the MSA subjects
was 58.1  9.3, which is similar to that in other se-
ries.2,16,17 Sixty percent of the MSA subjects were men,
which is consistent with previous reports.2,17 More than
half (57%) of the subjects had the MSA-P form, with the
remaining samples split about equally between MSA-C
(22%) and MSA-mixed (21%). The frequency of MSA-P
in this cohort is similar to that described in European
MSA cases.2,18 The vast majority of our MSA subjects
were white (94%), and this may reflect the referral pat-
terns of the 11 enrolling centers. The data are summa-
rized in Table 1.
We did not find the G2019S mutation in the LRRK2
gene in any of our 136 MSA subjects or 110 control
subjects. Our findings are consistent with previous stud-
ies of control cohorts.19,20
DISCUSSION
This is the first screening of a large cohort of MSA
patients for the G2019S mutation in the LRRK2 gene.
The G2019S mutation is found in about 1% of sporadic
PD patients.9 If this mutation were found at a similar
frequency in MSA as is observed in sporadic PD, we
would expect 1 to 2 of our MSA subjects to carry the
G2019S mutation, but we did not observe this mutation
in any of our cases. Although our power to detect a
mutation frequency substantially lower than this is lim-
ited, it is clear from our data that this mutation is not a
major risk factor for MSA. A recent study of 14 muta-
LRRK2 G2019S MUTATION NOT FOUND IN MSA 547
Movement Disorders, Vol. 22, No. 4, 2007
tions in the LRRK2 gene in parkinsonian subjects from
Singapore did not find any mutations in the gene in 15
MSA subjects.10 Ross et al.20 did not detect the G2019S
mutation in 43 pathologically confirmed cases of MSA.
The absence of the G2019S mutation in control subjects
is similar to that reported by other groups.19–21 The
G2019S mutation is infrequent in Alzheimer’s disease,
progressive supranuclear palsy, and frontotemporal
dementia.20,22–24
It should be noted that the cases initially reported by
Zimprich et al.6 to have pathology not typical of PD were
associated with the Y1699C and R1441G mutations in
the LRRK2 gene. However, studies of the pathology of
cases with the G2019S mutation20,25 have revealed clas-
sical changes of PD with Lewy bodies, but also changes
of PD without Lewy bodies. In some cases, senile
plaques and neurofibrillary tangles in the cortex were
also found.
LRRK2 is encoded by 51 exons and is an unusually
large protein with 2,527 amino acids.12 It has a number
of functional domains including two enzymatic regions:
ankyrin repeat region, leucine-rich repeat domain, Ras of
complex, C terminal of Ras, protein kinase, and WD40
domain. It is conceivable that mutations in other regions
of this complex and multifunctional molecule may be
associated with the Parkinsonism and synuclein inclu-
sions of MSA. However, we have carefully reviewed the
reports of LRRK2 mutations other than G2019S in par-
kinsonian disorders, and found that they have typically
been found in only one or a few families, or in isolated
populations. A recent screen of 458 patients with late-
onset PD or Parkinson’s plus syndromes (including 15
cases of MSA) for 14 mutations in the LRRK2 gene
found a single PD case with an R1441C mutation
(0.26%).10 Given the rarity of mutations other than
G2019S, it is unlikely that these very rare mutations
occur in our cohort, which did not include familial cases,
and was recruited throughout the United States.
In summary, our screening of the largest cohort of
patients with probable MSA reported to date indicated
that the G2019S mutation in the LRRK2 gene is unlikely
to be associated with the disorder.
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